Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634751 · ClinicalTrials.gov registry record · Phase 1
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
A Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00634751: Completed Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms, sponsored by University of Wisconsin, Madison.
NCT00634751 is a Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 48 participants, below the 600-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634751, a Phase 1 study of Pancreatic Neoplasms and Bile Duct Neoplasms, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract; however the combination has been tested in a preliminary trial. We are also testing a survey designed. The purpose of this research study is to investigate the chemotherapy drug sorafenib in combination with oxaliplatin and capecitabine chemotherapies for the treatment of pancreas and biliary tract cancers.to help patients report their side effects from chemotherapy treatments.
Primary Outcome
Response rate of participant to treatment
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Sorafenib
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
What the finished NCT00634751 record still lists
NCT00634751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 600-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT00634751 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00634751 about?
NCT00634751 is a clinical study titled "CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma". This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract...
What is the current status of trial NCT00634751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-02. Estimated completion is 2010-07.
What conditions does trial NCT00634751 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms, Bile Duct Neoplasms.
What interventions are being tested in trial NCT00634751?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00634751?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00634751 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00634751's enrollment target sits among peer trials
48 17th of 30 higher than 14 of 30 other Pancreatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
-
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia